Katheryne Richardson, PharmD

Managing Director at Berkeley Research Group, LLC

Speaker

Katheryne Richardson, PharmD, is a Managing Director in BRG’s Health practice and has over 25 years of experience including pharmacy practice, strategic consulting, drug pricing and policy analytics, and pharmaceutical industry executive leadership. She has specific expertise in the strategy, operations, and analytics of programs such as the 340B program and the Inflation Reduction Act (IRA). She specializes in leveraging technology enablement to support strategic consulting for clients across the healthcare continuum, including pharmaceutical manufacturers and others. Specifically, she focuses on creating strategic insights and opportunities that expand clients’ capabilities to understand, deliver, and optimize their performance in the dynamic drug pricing and policy landscape.

In her former role as Vice President Global Pricing and Health Systems Analytics for Bristol Myers Squibb, she led a large international team and had responsibility for US and WW pricing strategy and execution, contract operations, US government pricing, and pricing policy analytics functions. She served as the pricing lead for the first round of CMS IRA price-setting for the highest gross sales Medicare Part D drug, which included oversight of the pricing strategy, data submission, impact analytics, delivering executive communications and recommendations, and representing the pharmaceutical manufacturer in all live CMS meetings.

Additionally, while at BMS she had oversight for establishing and approving pricing and contracting strategies for new product launches, determining international reference pricing impacts for market segment pricing exceptions, overseeing the pricing governance and exception processes, projecting product/pricing impacts for potential business development opportunities, recommending price actions, overseeing and explaining market access components to the gross to net impacts in conjunction with finance, reporting state and federal government pricing requirements, approving rebate payments, preparing executive colleagues for pricing topics pertinent to earnings calls, congressional testimony, litigation, and other external affairs. In a prior role at BMS, she was Executive Director of 340B Strategy, where she led a cross-functional team to ensure creation and alignment of 340B strategy and successful execution of that strategy.

Prior to joining Bristol-Myers Squibb, Katheryne was Vice President of Apexus, the 340B Prime Vendor Program, and earlier in her career, Katheryne worked as a pharmacist practitioner and consultant with private organizations and government agencies such as the Food and Drug Administration, National Institutes of Health, and the Center for Disease Control. She is a speaker and author on drug pricing and policy topics such as 340B and the Inflation Reduction Act. Katheryne is a graduate of the University of Kentucky College of Pharmacy, receiving B.S. and PharmD degrees and is a licensed pharmacist. She currently resides in Virginia Beach, Virginia, with her husband and six children.